We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Merck & Co Inc | LSE:0QAH | London | Ordinary Share | MERCK & CO ORD (CDI) |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -0.40 | -0.30% | 131.00 | 125.80 | 136.20 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 7,483 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 60.12B | 365M | 0.1440 | 910.42 | 332.21B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/4/2024 | 12:13 | ALNC |  Merck & Co raises annual outlook thanks to first quarter boost |
| 15/3/2024 | 15:23 | ALNC | IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda |
| 20/2/2024 | 21:15 | ALNC | Merck and Astellas drugs get priority review in US and Japan |
| 01/2/2024 | 12:57 | ALNC | TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit |
| 19/1/2024 | 11:29 | ALNC | IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale |
| 08/1/2024 | 14:20 | ALNC | Merck to buy Harpoon Therapeutics for about USD680 million |
| 18/12/2023 | 11:04 | ALNC | Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev |
| 15/12/2023 | 08:41 | ALNC | Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit |
| 11/12/2023 | 17:56 | ALNC | Merck reports mixed updates for cancer treatment, Keytruda |
| 26/10/2023 | 12:17 | ALNC | TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge |
1 Year Merck & Chart |
Intraday Merck & Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
